Antineoplastics
1
Reactions 498 - 23 Apr 1994 Antineoplastics Secondary malignancies in patients with Hodgkin’s disease: incidence study Results of a Danish study found that patients with Hodgkin’s disease who were treated with antineoplastic therapy and/or radiotherapy had a 20% mean 20-year actuarial risk of developing secondary cancers. 1146 men and 793 women treated for Hodgkin’s disease were followed for a median of 9.2 years. Overall, 146 patients developed a secondary cancer, compared with 42 cases which would be expected in the general population (relative risk, 3.5). Significantly elevated risks were observed for leukaemia (34.7), non-Hodgkin’s lymphoma (20.6), lung cancer (3.7), GI cancers (2.0), all urogenital cancers (2.4), melanoma (4.9) and soft tissue sarcoma (8.8). An increased risk of developing leukaemia was associated with age > 40 years at diagnosis of Hodgkin’s disease, and first year treatment and follow-up treatment with antineoplastic therapy. Risk factors associated with developing non- Hodgkin’s lymphoma were age, male sex, and combined antineoplastic and radiotherapy, especially if given during the first year of treatment. Author comment: ‘The occurrence of treatment-related SCs [second cancers] following HD [Hodgkin’s disease] . . . must be viewed in relation to the dramatic increase in survival experienced by HD patients over the past decades . . . From the early 1980s onwards, new treatment strategies in HD have focused on the new development of therapeutic regimens with less leukemogenic potential.’ Van Leeuwen FE, et al. Second cancer risk following Hodgkin’s disease: a 20-year follow-up study. Journal of Clinical Oncology 12: 312-325, Feb 1994 - Netherlands 800256976 1 Reactions 23 Apr 1994 No. 498 0114-9954/10/0498-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Transcript of Antineoplastics
Reactions 498 - 23 Apr 1994
Antineoplastics
Secondary malignancies in patients with Hodgkin’sdisease: incidence study
Results of a Danish study found that patients with Hodgkin’sdisease who were treated with antineoplastic therapy and/orradiotherapy had a 20% mean 20-year actuarial risk ofdeveloping secondary cancers.
1146 men and 793 women treated for Hodgkin’s diseasewere followed for a median of 9.2 years. Overall, 146 patientsdeveloped a secondary cancer, compared with 42 cases whichwould be expected in the general population (relative risk,3.5). Significantly elevated risks were observed for leukaemia(34.7), non-Hodgkin’s lymphoma (20.6), lung cancer (3.7), GIcancers (2.0), all urogenital cancers (2.4), melanoma (4.9) andsoft tissue sarcoma (8.8).
An increased risk of developing leukaemia was associatedwith age > 40 years at diagnosis of Hodgkin’s disease, and firstyear treatment and follow-up treatment with antineoplastictherapy. Risk factors associated with developing non-Hodgkin’s lymphoma were age, male sex, and combinedantineoplastic and radiotherapy, especially if given during thefirst year of treatment.
Author comment: ‘The occurrence of treatment-related SCs[second cancers] following HD [Hodgkin’s disease] . . . must beviewed in relation to the dramatic increase in survivalexperienced by HD patients over the past decades . . . From theearly 1980s onwards, new treatment strategies in HD havefocused on the new development of therapeutic regimens withless leukemogenic potential.’Van Leeuwen FE, et al. Second cancer risk following Hodgkin’s disease: a 20-yearfollow-up study. Journal of Clinical Oncology 12: 312-325, Feb 1994 -Netherlands 800256976
1
Reactions 23 Apr 1994 No. 4980114-9954/10/0498-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
